-
Atypical femoral fractures reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis.
-
Risks of Nicobrevin outweigh any benefits.
-
Reminder to monitor and manage weight, glucose, and lipid levels.
-
-
Differences in dose delivery between the pump device and dropper device for memantine.
-
Insufficient evidence to confirm a link between oral bisphosphonate use and an increased risk of oesophageal cancer.
-
All healthcare professionals trained in inserting Implanon must make sure they are trained in using Nexplanon before the changeover.
-
Healthcare professionals should be aware of epidemiological data showing a small increased risk of fractures associated with the use of TCAs and SSRIs, and should take this risk into account in their discussions with patient…
-
Epidemiological data suggest that the use of SSRIs in pregnancy, particularly in the later stages, may increase the risk of persistent pulmonary hypertension in the newborn. Healthcare professionals are encouraged to enquire…
-
Recent epidemiological evidence suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen with paroxetine. There are insufficient data to d…
-
The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers
-
All patients with cancer should have a dental check-up before bisphosphonate treatment.
-
The study found no clear evidence that varenicline was associated with an increased risk of fatal or non-fatal self-harm.
-
Patients with existing meningioma or a history of meningioma must not be prescribed high-dose (≥25 mg per day) cyproterone acetate.
-
Use of Antipsychotic may be associated with an increased risk of venous thromboembolic events.
-
These medicines are not first-line options for insomnia.
-
Updated guidance to use methylphenidateto safely and effectively for attention deficit hyperactivity disorder (ADHD) in children of 6 years or older and adolescents.
-
Atomoxetine is associated with treatment-emergent psychotic or manic symptoms in children and adolescents - consider stopping this if symptoms occur.
-
Clinical trial results suggest an increased risk of atrial fibrillation for zoledronic acid (Aclasta▼), pamidronic acid, and possibly for alendronic acid, although the balance-risk remains favourable for bisphosphonates.
-
Latest evidence suggests long-term use of combined oral contraceptives or progestogen-only injectable contraceptives is associated with a small increased risk of cervical cancer.
-
New study shows use of oral contraceptives reduces risk of ovarian cancer.
-
Summary report on the risk of suicidal thoughts and behaviour related to antidepressants.
-
Breastfed babies might very rarely develop side-effects due to the presence of morphine in breast milk.
-
To avoid the risk of air embolism, these products should not be infused under pressure.
-
Products that contain botulinum toxin are associated with the risk of serious adverse reactions due to distant spread of toxin.
-
Maximum dose of lorazepam for short term, symptomatic treatment is 4 mg per day for severe, disabling anxiety, and 2 mg per day for severe, disabling insomnia
-
Rare occurrence of serious allergic reactions should not preclude use of parenteral thiamine in patients who need treatment by this route of administration.
-
Increased risk of stroke in older women should be taken into account in prescribing decisions.
-
Patients should be assessed regularly due to reported cases of suicidal ideation and suicidal behaviour during treatment with duloxetine or shortly after stopping treatment.
-
Before prescribing hormone-replacement therapy, healthcare professionals should consider carefully the potential benefits and risks for every woman